Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Intravenous iron in patients with heart failure and reduced ejection fraction (HFREF) plus iron deficiency: Effects upon phosphate and FGF23 metabolism

Trial Profile

Intravenous iron in patients with heart failure and reduced ejection fraction (HFREF) plus iron deficiency: Effects upon phosphate and FGF23 metabolism

Completed
Phase of Trial: Phase II

Latest Information Update: 26 Dec 2017

At a glance

  • Drugs Ferric carboxymaltose (Primary)
  • Indications Chronic heart failure; Iron deficiency anaemia
  • Focus Therapeutic Use
  • Acronyms Iron Turtle
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 05 Dec 2017 Status changed from recruiting to completed.
    • 18 Apr 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top